Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma

摘要

Bevacizumab's effects on contrast enhancement in high-grade glioma have created new challenges in determining tumor progression, eventuating in the adoption of the new RANO criteria. Moreover, animal models demonstrate that bevacizumab predisposes to development of a more invasive tumor phenotype characterized by T2/FLAIR signal abnormality distant from the original site of tumor. The frequency of this occurrence in human glioblastoma and its relationship to antiangiogenic treatment have been debated.